Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

PRIMARY OBJECTIVES:

I. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis
differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide
compared to male controls without a history of cancer.

II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma
alters sperm deoxyribonucleic acid (DNA) methylation.

SECONDARY OBJECTIVES:

I. Evaluate the role of genetic susceptibility in the development of impairments in
spermatogenesis or steroidogenesis with contemporary regimens for the treatment of
osteosarcoma.

OUTLINE:

Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva
and semen samples and undergo collection of blood.

Inclusion Criteria:

- Living

- Previously enrolled and randomized on AOST0331 or INT0133 (also known as CCG7921 and
POG9351)

- Osteosarcoma survivors without relapse or a subsequent malignancy other than skin
cancer following initial treatment on AOST0331 or INT0133 (also known as CCG7921 and
POG9351)

- Able to speak, read and write in English or Spanish

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met